Feb 12 (Reuters) - Alto Neuroscience ANRO.N:
ALTO NEUROSCIENCE ANNOUNCES FAVORABLE OUTCOME FROM INTERIM ANALYSIS OF ALTO-300 PHASE 2B MAJOR DEPRESSIVE DISORDER TRIAL
ALTO NEUROSCIENCE INC -TOPLINE RESULTS ARE EXPECTED IN MID-2026
Source text: ID:nBw12H1ra
Further company coverage: ANRO.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.